S59 New Roles for Relaxin in Health and Disease

Program: Symposia
Basic/Translational Session
Sunday, April 3, 2016: 4:45 PM-6:15 PM
Room 253 (BCEC)
Robert G. Bennett, PhD, VA Nebraska-Western Iowa Health Care System, Omaha, NE

Nothing to Disclose: RGB
4:45 PM
Chrishan S Samuel, PhD, Department of Pharmacology (Building 13E), Monash University, Clayton VIC, Australia
Nothing to Disclose: CSS
5:15 PM
Kirk P Conrad, MD, Departments of Physiology and Functional Genomics, and of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL
KPC: Ad Hoc Consultant, Novartis Pharmaceuticals, Principal Investigator, Novartis Pharmaceuticals, Teacher, Novartis Pharmaceuticals, Other activities, please specify:, Novartis Pharmaceuticals.
5:45 PM
Ravinder Anand-Ivell, PhD, FRSB, School of Biosciences, University of Nottingham, United Kingdom
Nothing to Disclose: RA
See more of: Symposia


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire